4°C for short term (1 week), -20°C or -80°C for long term (avoid freezing/thawing cycles; addition of 20-40% glycerol improves cryoprotection)
Brand
ProteoGenix
Host species
Mammalian cells
Fragment Type
Met1-Arg370
Aliases /Synonyms
BIT, Signal-regulatory protein alpha-1, Brain Ig-like molecule with tyrosine-based activation motifs, MFR, SIRP, Sirp-alpha-1, Sirp-alpha-2, PTPNS1, SIRPA, SHP substrate 1, CD172 antigen-like family member A, Sirp-alpha-3, Inhibitory receptor SHPS-1, Signal-regulatory protein alpha-3, CD172a, Tyrosine-protein phosphatase non-receptor type substrate 1, MyD-1 antigen, Bit, SHPS-1, Macrophage fusion receptor, Signal-regulatory protein alpha-2, SHPS1, MYD1, p84
Reference
PX-P6120
Note
For research use only
Description of Human CD172a-SIRPA recombinant protein
General information on Human CD172a-SIRPA recombinant protein
Structure
Human CD172a-SIRPA recombinant protein is a type I transmembrane glycoprotein composed of two extracellular Ig-like domains, a transmembrane domain, and a short cytoplasmic tail. It is encoded by the SHPS-1 gene.
Activity
CD172a-SIRPA protein is a member of the immunoglobulin superfamily that is involved in the regulation of cell-cell interactions. It is known to bind to the CD47 receptor on other cells and inhibit their activation, making it an important immune checkpoint protein.
Application
CD172a-SIRPA recombinant protein has potential applications in the development of antibody-drug conjugates (ADCs) for cancer therapy. It can be used to target cancer cells by binding to CD47 receptors on their surface. This binding triggers an immune response that leads to the destruction of the cancer cells.
Reviews
There are no reviews yet.